Greenwich LifeSciences, Inc. (GLSI)
NASDAQ · Manufacturing · Pharmaceutical preparations
GLSI price, last 12 months
Key stats
- Previous close
- $20.58
- Open
- $20.54
- Day range
- $19.39 – $20.97
- 52-week range
- $7.78 – $34.10
- Volume
- 231.3K
- Avg volume (20 days)
- 218.4K
- Market cap
- $219.3M
Performance
Technicals and fundamentals
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $219.3M